Escorp Asset Management provides customized investment portfolio management and advisory services to high-net-worth individuals and corporate clients, earning revenue primarily through management fees and gains on its own proprietary investment holdings.
The company lacks a durable moat as evidenced by an average ROCE of 8.4%, which is likely near its cost of capital. While high net margins of 46% suggest low operating costs, they are driven by investment gains rather than pricing power or high switching costs in its core asset management service.
Management primarily reinvests earnings into the company's own investment book and inter-corporate deposits within the Aryaman group. There is a notable absence of dividends, with profits instead used for a bonus share issue in 2023 to capitalize reserves.
The investment collapsed as the illusion of profitability vanished when the equity markets soured. Because the company relied on investment gains rather than recurring fee-based income, a prolonged market downturn turned high net margins into deep losses. The capital tied up in inter-corporate deposits within the Aryaman group became illiquid or was lost to group-level distress, leaving shareholders with a shell company that lacked a functional operating business or independent management, as the directors remained beholden to the parent entity's payroll.
RichFakir rates Escorp Asset Management Ltd's business quality as mediocre — 51/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Escorp Asset Management Ltd is trading about 28% below our estimate of fair value; we rate its price fair. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Escorp Asset Management Ltd is: Not rated. A mediocre business at a fair price — it does not make our shortlist right now.
RichFakir's educational estimate of Escorp Asset Management Ltd's fair value is about ₹140 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →